Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Isolagen pivotal study

This article was originally published in The Gray Sheet

Executive Summary

Initial stage of 158-patient Phase III trial for autologous cellular skin therapy is completed. The technology, which the firm plans to launch in 2005, cultures a skin biopsy from behind the ear and implants newly grown fibroblasts in order to regenerate collagen (1"The Gray Sheet" Feb. 16, 2004, p. 16). Early study results show 77% efficacy at four months. Isolagen expects efficacy to improve over six months of follow-up...

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts